Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGiNAUT phase IIb study of AZD8965 in idiopathic pulmonary fibrosis
jRCT2041260087Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 2 trial of AZD8965 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by AstraZeneca. Primary endpoint: Absolute change from baseline in forced vital capacity. Started Aug 2026; status: recruiting.
02
Drugs
AZD8965
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2041260087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260087.